SubtypeDrug: a software package for prioritization of candidate cancer subtype-specific drugs

SUMMARY Cancer can be classified into various subtypes by its molecular, histological, or clinical characteristics. Discovering cancer-subtype-specific drugs is a crucial step in personalized medicine. SubtypeDrug is a system biology R-based software package that enables the prioritization of subtype-specific drugs based on cancer expression data from samples of many subtypes. This provides a novel approach to identify the subtype-specific drug by considering biological functions regulated by drugs at the subpathway level. The operation modes include extraction of subpathways from biological pathways, identification of dysregulated subpathways induced by each drug, inference of sample-specific subpathway activity profiles, evaluation of drug-disease reverse association at the subpathways level, identification of cancer-subtype-specific drugs through subtype sample set enrichment analysis, and visualization of the results. Its capabilities enable SubtypeDrug to find subtype-specific drugs, which will fill the gaps in the recent tools which only identify the drugs for a particular cancer type. SubtypeDrug may help to facilitate the development of tailored treatment for patients with cancer. AVAILABILITY AND IMPLEMENTATION The package is implemented in R and available under GPL-2 license from the CRAN website (https://CRAN.R-project.org/package=SubtypeDrug). SUPPLEMENTARY INFORMATION Supplementary data are available at Bioinformatics online.

[1]  Ying Jiang,et al.  Prioritization of candidate cancer drugs based on a drug functional similarity network constructed by integrating pathway activities and drug activities , 2019, Molecular oncology.

[2]  Paul A Clemons,et al.  The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease , 2006, Science.

[3]  Junwei Han,et al.  psSubpathway: a software package for flexible identification of phenotype-specific subpathways in cancer progression , 2019, Bioinform..

[4]  Julio Saez-Rodriguez,et al.  DvD: An R/Cytoscape pipeline for drug repurposing using public repositories of gene expression data , 2012, Bioinform..

[5]  Chunquan Li,et al.  SubpathwayMiner: a software package for flexible identification of pathways , 2009, Nucleic acids research.

[6]  P. Sanseau,et al.  Drug repurposing: progress, challenges and recommendations , 2018, Nature Reviews Drug Discovery.

[7]  Qianlan Yao,et al.  Subpathway-GM: identification of metabolic subpathways via joint power of interesting genes and metabolites and their topologies within pathways , 2013, Nucleic acids research.

[8]  Minoru Kanehisa,et al.  KEGG as a reference resource for gene and protein annotation , 2015, Nucleic Acids Res..

[9]  Pietro Lio',et al.  Pathway-based subnetworks enable cross-disease biomarker discovery , 2018, Nature Communications.

[10]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[11]  Justin Guinney,et al.  GSVA: gene set variation analysis for microarray and RNA-Seq data , 2013, BMC Bioinformatics.